Barbara Finck, MD

Self
San Francisco, CA, United States

Dr. Finck is an internist and rheumatologist with more than 25 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings. Dr. Finck, whose drug development activities have spanned multiple therapeutic areas and multiple development phases, She recently serves as an advisor to Coherus BioSciences where she served as Chief Medical Officer for the past 10 years developing biosimilars, such as pegfilgrastim-cbqv and adalibmumab-aqvh.

Disclosure information not submitted.

Presentation(s):

• 1832: Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time